Periodontal DiseasesPhase 2NCT00133926
Prevention of Pre-Term Birth by Treatment of Periodontal Disease
A Phase 2 study testing Treatment of periodontal disease in people with Periodontal Diseases and Premature Birth, run by King Edward Memorial Hospital at 1 site in Australia.
Trial summary
The aim of the study is to investigate, in an Australian population of pregnant women, whether the treatment of periodontal disease during pregnancy prevents pre-term birth and other complications of pregnancy. Read more about this study
- Who is it for?
- Ages 16 years and older, women only
- Conditions the study is for
- Periodontal Diseases, Premature Birth, Pre-Eclampsia
- What is being tested?
- Treatment of periodontal disease
- Type of treatment
- Surgery or procedure
- How many people
- 1,094 participants
- Where
- 1 siteAustralia
- Study dates
- Mar 2005to Jun 2008
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 years and older
- Women only
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Pregnant women, with single pregnancies, between 12 and 20 weeks gestation
- Periodontal disease defined as periodontal pocketing at a threshold of 4mm or more at 10% or more of sites
- Agree to receive periodontal treatment
Who cannot join
- Unable to attend for treatment
- Less than 16 years of age
- Have a fetus with an abnormality that predisposes the pregnancy to pre-term birth
- Multiple pregnancy
- Cardiac disease that would require antibiotic therapy
- Have fewer than 20 teeth
Show all 9Show fewer
- Present for antenatal care after 20 weeks gestation
- Unable to understand the implications of participation in the trial
- Currently receiving periodontal treatment
Trial locations and contacts
1 site in 1 country.
Australia1 site, 1 recruiting
- Recruiting
King Edward Memorial Hospital, Bagot Rd, Subiaco
Perth, Western Australia, 6008
John P Newnham, MD, FRANZCOG, 61 8 93401331, jnewnham@obsgyn.uwa.edu.au
Dorota Doherty, PhD, 61 8 93401627, ddoherty@obsgyn.uwa.edu.au
About this study
Official title: Prevention of Pre-Term Birth by Treatment of Periodontal Disease During Pregnancy - The Smile Study
The aim of the study is to investigate, in an Australian population of pregnant women, whether the treatment of periodontal disease during pregnancy prevents pre-term birth and other complications of pregnancy. Dental screening and periodontal treatment protocols have been based on standard techniques employed by hygienists that can be readily applied to the general obstetric population.
Read the detailed description
HYPOTHESES
Primary Hypothesis:
That treatment of periodontal disease during pregnancy reduces the rate of pre-term birth from 12% to 7%.
Secondary Hypothesis:
That treatment of periodontal disease during pregnancy reduces the rate of:
- Fetal growth restriction.
- Complications of pre-term birth including respiratory distress syndrome.
- Periodontal disease measured at 36 weeks gestation.
Research Plan Synopsis:
A randomized controlled trial is being conducted with recruitment of women from the antenatal clinics of Perth's major obstetric centres and associated private practices. The sample is being enriched by inviting women with a history of poor oral health or pre-term birth. 5400 eligible women will undergo a hygienist-based screening study at 12-20 weeks gestation. 1094 women who meet the criteria for periodontal disease determined from our recent pilot study will be allocated at random to the treatment or control groups. Those in the treatment group will receive three one-hour hygienist-based periodontal treatment sessions commencing at 20 weeks gestation, followed by re-examination at 26 weeks. Re-treatment will be offered to the 5% of cases in which treatment has been ineffective, and ongoing maintenance to the remainder. Women allocated to the control group will be offered similar treatment after completion of the pregnancy.
RESEARCH PLAN
Study Design:
Multi-centered single-blinded randomized controlled trial conducted within the metropolitan area of Perth, Western Australia. The obstetric and newborn health care providers are blinded to the periodontal treatment allocation.
Inclusion Criteria:
Women with single pregnancies at 12 to 20 weeks gestation with periodontal disease defined as periodontal pocketing at a threshold of 4mm or more at 10% or more of sites and who agree to receive periodontal treatment are eligible. The definition of periodontal disease is based on the published literature and our pilot study designed to determine the prevalence in our local obstetric population. Periodontal pocketing is used to define the presence of periodontal disease rather than clinical loss of attachment because it better represents the microbial challenge and is the most frequently employed criterion. In our pilot study, 15% of our general unselected population met this criterion.
Exclusion Criteria:
Women are ineligible if they are: unable to attend for periodontal treatment; less than 16 years of age; present for antenatal care after 20 weeks gestation; are unable to understand the implications of participation in the trial; have a fetus with a known abnormality that would predispose the pregnancy to pre-term birth such as those that may cause polyhydramnios; have a multiple pregnancy; have cardiac disease that would require antibiotic therapy for dental treatment; are currently receiving periodontal treatment; or have fewer than 20 teeth.
Trial Entry:
All women planning to attend the antenatal clinics at King Edward Memorial Hospital (KEMH) in Perth, Western Australia are provided with written information about the trial with their appointment letter. Those attending other public antenatal clinics and a proportion of private practices also receive the information and invitation. Women who do not have exclusion criteria are invited by a research midwife to provide written informed consent to undergo a periodontal examination. After the examination those women who meet the criteria for periodontal disease are invited by a member of the research team to participate in the trial and to provide written informed consent to have treatment. A questionnaire is administered to obtain data on demographic and medical factors that may influence oral health and details of past and present dental care. Women who are found to not have periodontal disease are asked to provide consent for their obstetric outcomes to be retrieved from the state-wide computerized data collection system that encompasses all births in Western Australia.
Randomisation:
Each woman is allocated to the treatment or control group by the sealed-envelope technique, prepared in blocks of 20. Recruitment is stratified by history of pre-term birth, nulliparity and smoking practice. Women who smoke in either arm of the study are provided with written material encouraging them to cease smoking.
Management of the Treatment Group:
Women allocated to the treatment group are given appointments to attend the Oral Health Centre of Western Australia (OHCWA).
Management of the Control Group:
Women allocated to the control group are provided with the findings of their periodontal examination to take to their dentist and written information on oral health care. Each woman is also invited to receive free dental care at OHCWA commencing 6 weeks after delivery and continuing for 16 weeks, as described below.
Dental Examination:
The simple screening dental examination is a modified WHO CPITN (Gjermo,1998) conducted in a well-equipped dental room within the antenatal clinic at KEMH. This examination takes approximately 20 minutes and is conducted by a study hygienist under supervision by the study periodontists. If periodontitis is detected the woman is invited to participate in the trial as described previously.
Periodontal Treatment:
Treatment Group:
All periodontal treatment is conducted in the Oral Health Centre of Western Australia (OHCWA), located 2 km from KEMH. A full periodontal examination is first performed using a constant force automated Florida probe (Florida Probe Corporation, Gainesville, Florida, USA) which provides precise measurements of pocket depth to 0.2mm, and stores data directly into a computer. This measurement system has been used in our pilot study and two separate probes and computer systems are available for this trial. Further periodontal parameters are recorded, including clinical attachment loss, full mouth bleeding after probing, and modified O'Leary Plaque Index. Treatment explanation is then provided by the hygienist and consent confirmed. The treatment plan for each woman is determined in consultation with a study periodontist and is conducted over 3 visits each of one hour duration. These treatments consist of non-surgical debridement of the sub- and supra-gingival plaque, removal of local predisposing factors such as calculus, and adjustment of overhanging restorations. Comprehensive oral hygiene instruction and motivation is provided at each visit as required. This oral hygiene advice recommends tooth brushing and flossing after every meal and rinsing with 0.12% non-alcohol based chlorhexidine mouth wash. These treatments are provided on 3 occasions at weekly intervals commencing at 20 weeks gestation.
Local anaesthesia is employed as required (1% lignocaine with 1:80,000 adrenalin up to a maximum dose of 10mls).
Four weeks after the final treatment, at approximately 28 weeks gestation, a further visit is made to re-evaluate periodontal status using clinical examination and the Florida probe. This examination provides a quantifiable assessment of the success of treatment. Those women in whom treatment has been unsuccessful are offered a further 3-visit treatment plan and we estimate this will be required in 5-10% of the sample. A further two visits, each of 45 minutes duration is scheduled for 32 and 36 weeks gestation, at which times periodontal supportive care and oral hygiene instruction and motivation are carried out as required. Periodontal parameters at these visits are recorded.
Full infection control barrier techniques are employed and are stringent. Procedures include gowns, disposable gloves and masks, eye protection for examiner and patient, and barrier methods to avoid contamination.
Systemic antibiotic treatment is not employed except in cases in which there is evidence of multiple periodontal abscesses, impaired immune response or poorly controlled diabetes. In such cases treatment involves oral metronidazole and amoxycillin in standard doses for 5 days commencing with the treatment. In the pilot study we observed no cases meeting these criteria.
Control Group:
Women allocated to the control group are offered periodontal care after birth commencing 6 weeks after delivery. This care involves the same initial assessment and 3-visit treatment protocol as for women in the treatment group. A further full periodontal examination is conducted 4 weeks later.
After completion of their involvement in the study, women in both groups will be offered ongoing maintenance care at OCHWA and this care will be free of charge if they hold a health care card.
Women Who Deliver Pre-Term:
Those women who deliver pre-term will be offered a further screening examination at OHCWA and treatment as for the control group. Information in this regard will be provided at the time of recruitment.
Obstetric Management:
The obstetric and midwifery health care providers are unaware of the treatment allocation of each woman in the study. Care is provided according to the standard protocols employed within each hospital.
Sample Size:
The sample is enriched by advertising in the general media and in our peripheral public hospitals for women with poor oral health or a history of pre-term birth to attend KEMH for a single visit between 12 and 20 weeks gestation for periodontal examination.
A sample size of 540 women in each arm provides power to detect a reduction in the rate of pre-term birth from 12% to 7% with power of 90% and an alpha level of 5%. Our pilot study of 272 women revealed a rate of periodontal disease of 15% in unselected women. With enrichment by advertising for women at higher risk, we estimate the rate of periodontal disease will be 20%. Thus, for a total study size of 1080 women, 5400 need to be screened, which is rate of 45 each week in a 48 week working year. This sample size estimate allows two interim analyses.
Statistical Considerations:
A data monitoring committee will be formed and will include an independent statistician who will conduct the interim analysis. The committee will cease the trial if pre-determined rates of benefit or harm are achieved. Analyses will be conducted on an intention-to-treat basis using tests of proportions and logistic regression that allow for multiple adjustment for covariates. Secondary analyses will be conducted of dose-response of treatment and appropriate comparisons made with women who received periodontal examinations but did not meet eligibility criteria. All hypothesis testing will be two sided and significance will be at the 5% level.
- Conditions
- Periodontal Diseases, Premature Birth, Pre-Eclampsia
- Being tested
- Treatment of periodontal disease
- Keywords
- Periodontal disease, Pregnancy, Pre-term birth, Fetal growth, Pre-eclampsia, Infant, Low Birth Weight
- Medical subject headings
- Periodontal Diseases, Premature Birth, Pre-Eclampsia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Treatment of periodontal diseaseProcedure or surgery
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of pre-term birth
Secondary outcomes (3)
Rate of fetal growth restriction
Rate of pre-eclampsia
Rate of complications of pre-term birth
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Aug 2005 (estimated)
- Study startMar 2005
- Study completionJun 2008 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Periodontal DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 1,094 participants
Sponsor and investigators
- Lead sponsor
- King Edward Memorial Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- The University of Western Australia
- Investigators
- John P Newnham, MD, FRANZCOG, Principal investigator, The University of Western Australia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00133926
- Sponsor's protocol ID
- 353577
- Other IDs
- NHMRC Australia 353577
- Status last verified
- Apr 2007
- First submitted
- 23 Aug 2005
- Last updated
- 5 Apr 2007
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Newnham JP, Newnham IA, Ball CM, Wright M, Pennell CE, Swain J, Doherty DA. Treatment of periodontal disease during pregnancy: a randomized controlled trial. Obstet Gynecol. 2009 Dec;114(6):1239-1248. doi: 10.1097/AOG.0b013e3181c15b40.
PubMed 19935025
Study at a glance
From the registry record, last updated by the sponsor on 5 Apr 2007. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevention of Pre-Term Birth by Treatment of Periodontal Disease During Pregnancy - The Smile Study
- ClinicalTrials.gov ID
- NCT00133926
- Acronym / sponsor ID
- 353577
- Conditions
- Periodontal Diseases, Premature Birth, Pre-Eclampsia
- Keywords
- Periodontal disease, Pregnancy, Pre-term birth, Fetal growth, Pre-eclampsia, Infant, Low Birth Weight
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 1,094 participants
- Lead sponsor
- King Edward Memorial HospitalUniversity, hospital or other
- Collaborators
- The University of Western Australia
- Study start
- Mar 2005
- Study completion
- Jun 2008 (estimated)
- First posted
- 24 Aug 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to investigate, in an Australian population of pregnant women, whether the treatment of periodontal disease during pregnancy prevents pre-term birth and other complications of pregnancy. Dental screening and periodontal treatment protocols have been based on standard techniques employed by hygienists that can be readily applied to the general obstetric population.
Detailed description
HYPOTHESES
Primary Hypothesis:
That treatment of periodontal disease during pregnancy reduces the rate of pre-term birth from 12% to 7%.
Secondary Hypothesis:
That treatment of periodontal disease during pregnancy reduces the rate of:
- Fetal growth restriction.
- Complications of pre-term birth including respiratory distress syndrome.
- Periodontal disease measured at 36 weeks gestation.
Research Plan Synopsis:
A randomized controlled trial is being conducted with recruitment of women from the antenatal clinics of Perth's major obstetric centres and associated private practices. The sample is being enriched by inviting women with a history of poor oral health or pre-term birth. 5400 eligible women will undergo a hygienist-based screening study at 12-20 weeks gestation. 1094 women who meet the criteria for periodontal disease determined from our recent pilot study will be allocated at random to the treatment or control groups. Those in the treatment group will receive three one-hour hygienist-based periodontal treatment sessions commencing at 20 weeks gestation, followed by re-examination at 26 weeks. Re-treatment will be offered to the 5% of cases in which treatment has been ineffective, and ongoing maintenance to the remainder. Women allocated to the control group will be offered similar treatment after completion of the pregnancy.
RESEARCH PLAN
Study Design:
Multi-centered single-blinded randomized controlled trial conducted within the metropolitan area of Perth, Western Australia. The obstetric and newborn health care providers are blinded to the periodontal treatment allocation.
Inclusion Criteria:
Women with single pregnancies at 12 to 20 weeks gestation with periodontal disease defined as periodontal pocketing at a threshold of 4mm or more at 10% or more of sites and who agree to receive periodontal treatment are eligible. The definition of periodontal disease is based on the published literature and our pilot study designed to determine the prevalence in our local obstetric population. Periodontal pocketing is used to define the presence of periodontal disease rather than clinical loss of attachment because it better represents the microbial challenge and is the most frequently employed criterion. In our pilot study, 15% of our general unselected population met this criterion.
Exclusion Criteria:
Women are ineligible if they are: unable to attend for periodontal treatment; less than 16 years of age; present for antenatal care after 20 weeks gestation; are unable to understand the implications of participation in the trial; have a fetus with a known abnormality that would predispose the pregnancy to pre-term birth such as those that may cause polyhydramnios; have a multiple pregnancy; have cardiac disease that would require antibiotic therapy for dental treatment; are currently receiving periodontal treatment; or have fewer than 20 teeth.
Trial Entry:
All women planning to attend the antenatal clinics at King Edward Memorial Hospital (KEMH) in Perth, Western Australia are provided with written information about the trial with their appointment letter. Those attending other public antenatal clinics and a proportion of private practices also receive the information and invitation. Women who do not have exclusion criteria are invited by a research midwife to provide written informed consent to undergo a periodontal examination. After the examination those women who meet the criteria for periodontal disease are invited by a member of the research team to participate in the trial and to provide written informed consent to have treatment. A questionnaire is administered to obtain data on demographic and medical factors that may influence oral health and details of past and present dental care. Women who are found to not have periodontal disease are asked to provide consent for their obstetric outcomes to be retrieved from the state-wide computerized data collection system that encompasses all births in Western Australia.
Randomisation:
Each woman is allocated to the treatment or control group by the sealed-envelope technique, prepared in blocks of 20. Recruitment is stratified by history of pre-term birth, nulliparity and smoking practice. Women who smoke in either arm of the study are provided with written material encouraging them to cease smoking.
Management of the Treatment Group:
Women allocated to the treatment group are given appointments to attend the Oral Health Centre of Western Australia (OHCWA).
Management of the Control Group:
Women allocated to the control group are provided with the findings of their periodontal examination to take to their dentist and written information on oral health care. Each woman is also invited to receive free dental care at OHCWA commencing 6 weeks after delivery and continuing for 16 weeks, as described below.
Dental Examination:
The simple screening dental examination is a modified WHO CPITN (Gjermo,1998) conducted in a well-equipped dental room within the antenatal clinic at KEMH. This examination takes approximately 20 minutes and is conducted by a study hygienist under supervision by the study periodontists. If periodontitis is detected the woman is invited to participate in the trial as described previously.
Periodontal Treatment:
Treatment Group:
All periodontal treatment is conducted in the Oral Health Centre of Western Australia (OHCWA), located 2 km from KEMH. A full periodontal examination is first performed using a constant force automated Florida probe (Florida Probe Corporation, Gainesville, Florida, USA) which provides precise measurements of pocket depth to 0.2mm, and stores data directly into a computer. This measurement system has been used in our pilot study and two separate probes and computer systems are available for this trial. Further periodontal parameters are recorded, including clinical attachment loss, full mouth bleeding after probing, and modified O'Leary Plaque Index. Treatment explanation is then provided by the hygienist and consent confirmed. The treatment plan for each woman is determined in consultation with a study periodontist and is conducted over 3 visits each of one hour duration. These treatments consist of non-surgical debridement of the sub- and supra-gingival plaque, removal of local predisposing factors such as calculus, and adjustment of overhanging restorations. Comprehensive oral hygiene instruction and motivation is provided at each visit as required. This oral hygiene advice recommends tooth brushing and flossing after every meal and rinsing with 0.12% non-alcohol based chlorhexidine mouth wash. These treatments are provided on 3 occasions at weekly intervals commencing at 20 weeks gestation.
Local anaesthesia is employed as required (1% lignocaine with 1:80,000 adrenalin up to a maximum dose of 10mls).
Four weeks after the final treatment, at approximately 28 weeks gestation, a further visit is made to re-evaluate periodontal status using clinical examination and the Florida probe. This examination provides a quantifiable assessment of the success of treatment. Those women in whom treatment has been unsuccessful are offered a further 3-visit treatment plan and we estimate this will be required in 5-10% of the sample. A further two visits, each of 45 minutes duration is scheduled for 32 and 36 weeks gestation, at which times periodontal supportive care and oral hygiene instruction and motivation are carried out as required. Periodontal parameters at these visits are recorded.
Full infection control barrier techniques are employed and are stringent. Procedures include gowns, disposable gloves and masks, eye protection for examiner and patient, and barrier methods to avoid contamination.
Systemic antibiotic treatment is not employed except in cases in which there is evidence of multiple periodontal abscesses, impaired immune response or poorly controlled diabetes. In such cases treatment involves oral metronidazole and amoxycillin in standard doses for 5 days commencing with the treatment. In the pilot study we observed no cases meeting these criteria.
Control Group:
Women allocated to the control group are offered periodontal care after birth commencing 6 weeks after delivery. This care involves the same initial assessment and 3-visit treatment protocol as for women in the treatment group. A further full periodontal examination is conducted 4 weeks later.
After completion of their involvement in the study, women in both groups will be offered ongoing maintenance care at OCHWA and this care will be free of charge if they hold a health care card.
Women Who Deliver Pre-Term:
Those women who deliver pre-term will be offered a further screening examination at OHCWA and treatment as for the control group. Information in this regard will be provided at the time of recruitment.
Obstetric Management:
The obstetric and midwifery health care providers are unaware of the treatment allocation of each woman in the study. Care is provided according to the standard protocols employed within each hospital.
Sample Size:
The sample is enriched by advertising in the general media and in our peripheral public hospitals for women with poor oral health or a history of pre-term birth to attend KEMH for a single visit between 12 and 20 weeks gestation for periodontal examination.
A sample size of 540 women in each arm provides power to detect a reduction in the rate of pre-term birth from 12% to 7% with power of 90% and an alpha level of 5%. Our pilot study of 272 women revealed a rate of periodontal disease of 15% in unselected women. With enrichment by advertising for women at higher risk, we estimate the rate of periodontal disease will be 20%. Thus, for a total study size of 1080 women, 5400 need to be screened, which is rate of 45 each week in a 48 week working year. This sample size estimate allows two interim analyses.
Statistical Considerations:
A data monitoring committee will be formed and will include an independent statistician who will conduct the interim analysis. The committee will cease the trial if pre-determined rates of benefit or harm are achieved. Analyses will be conducted on an intention-to-treat basis using tests of proportions and logistic regression that allow for multiple adjustment for covariates. Secondary analyses will be conducted of dose-response of treatment and appropriate comparisons made with women who received periodontal examinations but did not meet eligibility criteria. All hypothesis testing will be two sided and significance will be at the 5% level.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
Who may qualify
- Ages
- 16 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (3 listed)
- Pregnant women, with single pregnancies, between 12 and 20 weeks gestation
- Periodontal disease defined as periodontal pocketing at a threshold of 4mm or more at 10% or more of sites
- Agree to receive periodontal treatment
Key exclusion criteria (9 listed)
- Unable to attend for treatment
- Less than 16 years of age
- Have a fetus with an abnormality that predisposes the pregnancy to pre-term birth
- Multiple pregnancy
- Cardiac disease that would require antibiotic therapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Treatment of periodontal disease | Procedure or surgery | – |
Primary outcome
Rate of pre-term birth
3 secondary outcomes
Rate of fetal growth restriction
Rate of pre-eclampsia
Rate of complications of pre-term birth
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Apr 2007.
- Derived from this study: PubMed 19935025Newnham JP, Newnham IA, Ball CM, Wright M, Pennell CE, Swain J, Doherty DA. Treatment of periodontal disease during pregnancy: a randomized controlled trial. Obstet Gynecol. 2009 Dec;114(6):1239-1248. doi: 10.1097/AOG.0b013e3181c15b40.
Related trials for Periodontal Diseases
Not yet recruitingObservational study
Periodontal Status and Biomarkers in MASLD
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Recruiting
Thermosensitive Hyaluronic Gel With Octenidine as an Adjunctive to Subgingival Instrumentation
Periodontal Disease
Active, not recruitingObservational study
A Retrospective Comparative Evaluation of Omega-3 and Resveratrol Supplementation in Patients With Periodontitis
Periodontitis
Recruiting
Effects of Different Activation Techniques on Antimicrobial Photodynamic Therapy in Apical Periodontitis
Apical Periodontitis, Endodontic Retreatment
Recruiting
Ozone Gel Versus Chlorohexidine Gel as an Adjunct to Non-Surgical Treatment of Stage II Periodontitis Grade B Among Smokers Patients
Ozone Gel, Chlorohexidine Gel
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
John P Newnham, MD, FRANZCOG principal investigator
The University of Western Australia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Treatment of periodontal disease in people with Periodontal Diseases and Premature Birth, run by King Edward Memorial Hospital at 1 site in Australia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 5 Apr 2007. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact John P Newnham, MD, FRANZCOG (61 9 9340 1331, jnewnham@obsgyn.uwa.edu.au), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of pre-term birth. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00133926, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Apr 2007.